Health Enhancement Products, Inc. Enters Into Collaborative Agreement With Global Animal Health Company to Accelerate Bovine Mastitis Product

KEEGO HARBOR, MI--(Marketwired - Dec 26, 2013) - Health Enhancement Products, Inc. (OTCQB: HEPI) has entered into a collaborative/option agreement with a global animal health company, whose name is being withheld for competitive considerations and intellectual property protection for both parties.

The terms of the agreement will allow Health Enhancement Products to move forward with validation and product development in direct collaboration with scientists from the animal health company. At pre-determined intervals of 90 days each for an evaluation period and a negotiation period which may culminate in a final licensing arrangement, additional opportunities to further disclose aspects of the agreement may occur.

The agreement provides for a licensing option covering bovine applications across a range of modalities, and includes the Company's natural compound, the proprietary refined algal extract and the synthetic molecules developed by Health Enhancement. Additional details may be released over the next few weeks.

Recently, the Company released notice of its early success in addressing mycoplasma bovis, a contagious pathogen responsible for a significant number of infections that result in bovine mastitis, and for which there exist limited treatment options.

About Health Enhancement Products, Inc.

Health Enhancement Products, Inc. (OTCQB: HEPI) is a health and wellness company engaged in the development of natural bioactive compounds for use as dietary supplements and food ingredients, as well as biologics for medicinal and pharmaceutical applications in humans and animals. The Company's scientific efforts are focused on the metabolic aspects of oxidation and inflammation, with a parallel program to validate and license products for healthy cholesterol balance.

Safe Harbor Statement

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.